169 related articles for article (PubMed ID: 32817201)
1. Value of pre-existent bacterial colonization in patients with advanced/relapsed ovarian neoplasms undergoing cytoreductive surgery: a multicenter observational study (BONSAI).
Fotopoulou C; Rinne N; Ghirardi V; Cunnea P; Drosou A; Tzovaras D; Giudice MT; Scambia G; Fagotti A
Int J Gynecol Cancer; 2020 Oct; 30(10):1562-1568. PubMed ID: 32817201
[TBL] [Abstract][Full Text] [Related]
2. Does timing of intraperitoneal chemotherapy initiation following primary cytoreductive surgery with bowel resection impact outcomes in patients with advanced ovarian cancer?
Nica A; Covens A; Parra-Herran C; May T
Gynecol Oncol; 2020 Sep; 158(3):622-630. PubMed ID: 32561124
[TBL] [Abstract][Full Text] [Related]
3. Predictive and Prognostic Implication of Bowel Resections During Primary Cytoreductive Surgery in Advanced Epithelial Ovarian Cancer.
Bartl T; Schwameis R; Stift A; Bachleitner-Hofmann T; Reinthaller A; Grimm C; Polterauer S
Int J Gynecol Cancer; 2018 Nov; 28(9):1664-1671. PubMed ID: 30371563
[TBL] [Abstract][Full Text] [Related]
4. Laparoscopic management of advanced epithelial ovarian cancer after neoadjuvant chemotherapy: a phase II prospective multicenter non-randomized trial (the CILOVE study).
Pomel C; Akladios C; Lambaudie E; Rouzier R; Ferron G; Lecuru F; Classe JM; Fourchotte V; Paillocher N; Wattiez A; Montoriol PF; Thivat E; Beguinot M; Canis M
Int J Gynecol Cancer; 2021 Dec; 31(12):1572-1578. PubMed ID: 34670829
[TBL] [Abstract][Full Text] [Related]
5. National trends in bowel and upper abdominal procedures in ovarian cancer surgery.
Dottino JA; He W; Sun CC; Zhao H; Fu S; Rauh-Hain JA; Suidan RS; Lu KH; Giordano SH; Meyer LA
Int J Gynecol Cancer; 2020 Aug; 30(8):1195-1202. PubMed ID: 32616627
[TBL] [Abstract][Full Text] [Related]
6. Clinical characteristics and outcomes after bowel surgery and ostomy formation at the time of debulking surgery for advanced-stage epithelial ovarian carcinoma.
Gockley AA; Fiascone S; Hicks Courant K; Pepin K; Del Carmen M; Clark RM; Goldberg J; Horowitz N; Berkowitz R; Worley M
Int J Gynecol Cancer; 2019 Mar; 29(3):585-592. PubMed ID: 30833444
[TBL] [Abstract][Full Text] [Related]
7. [Clinical observation of partial pancreatectomy as part of primary cytoreductive surgery in advanced epithelial ovarian cancer].
Xiang LB; Tu YX; He TC; Pei X; Shen XX; Yang WT; Wu XH; Yang HJ
Zhonghua Fu Chan Ke Za Zhi; 2016 May; 51(5):361-5. PubMed ID: 27256444
[TBL] [Abstract][Full Text] [Related]
8. Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial.
Shi T; Zhu J; Feng Y; Tu D; Zhang Y; Zhang P; Jia H; Huang X; Cai Y; Yin S; Jiang R; Tian W; Gao W; Liu J; Yang H; Cheng X; Zang R
Lancet Oncol; 2021 Apr; 22(4):439-449. PubMed ID: 33705695
[TBL] [Abstract][Full Text] [Related]
9. Unanticipated 30-day readmission following rectosigmoid resection at the time of cytoreductive surgery in patients with advanced stage ovarian cancer.
Sanders BE; Saharti S; Laus K; Bristow RE; Eskander RN
J Obstet Gynaecol; 2021 Aug; 41(6):956-961. PubMed ID: 33228421
[TBL] [Abstract][Full Text] [Related]
10. Post-operative pancreatic fistula following splenectomy with or without distal pancreatectomy at cytoreductive surgery in advanced ovarian cancer.
Bizzarri N; Korompelis P; Ghirardi V; O'Donnell RL; Rundle S; Naik R
Int J Gynecol Cancer; 2020 Jul; 30(7):1043-1051. PubMed ID: 32546641
[TBL] [Abstract][Full Text] [Related]
11. Bowel resection or repair at the time of cytoreductive surgery for ovarian malignancy is associated with increased complication rate: An ACS-NSQIP study.
Bernard L; Boucher J; Helpman L
Gynecol Oncol; 2020 Sep; 158(3):597-602. PubMed ID: 32641239
[TBL] [Abstract][Full Text] [Related]
12. Interval debulking surgery is not worth the wait: a National Cancer Database study comparing primary cytoreductive surgery versus neoadjuvant chemotherapy.
Lyons YA; Reyes HD; McDonald ME; Newtson A; Devor E; Bender DP; Goodheart MJ; Gonzalez Bosquet J
Int J Gynecol Cancer; 2020 Jun; 30(6):845-852. PubMed ID: 32341114
[TBL] [Abstract][Full Text] [Related]
13. Impact of postoperative morbidity on outcomes in patients with advanced epithelial ovarian cancer undergoing intestinal surgery at the time of primary or interval cytoreductive surgery: A Memorial Sloan Kettering Cancer Center Team Ovary study.
Praiss AM; Hirani R; Zhou Q; Iasonos A; Sonoda Y; Abu-Rustum NR; Leitao MM; Long Roche K; Broach V; Gardner GJ; Chi DS; Zivanovic O
Gynecol Oncol; 2023 Dec; 179():169-179. PubMed ID: 37992548
[TBL] [Abstract][Full Text] [Related]
14. Well-trained gynecologic oncologists can perform bowel resection and upper abdominal surgery safely.
Nishikimi K; Tate S; Kato K; Matsuoka A; Shozu M
J Gynecol Oncol; 2020 Jan; 31(1):e3. PubMed ID: 31788993
[TBL] [Abstract][Full Text] [Related]
15. Incorporating robotic surgery into the management of ovarian cancer after neoadjuvant chemotherapy.
Abitbol J; Gotlieb W; Zeng Z; Ramanakumar A; Kessous R; Kogan L; Pare-Miron V; Rombaldi M; Salvador S; Kucukyazici B; Brin S; How J; Lau S
Int J Gynecol Cancer; 2019 Nov; 29(9):1341-1347. PubMed ID: 31601648
[TBL] [Abstract][Full Text] [Related]
16. Maximal effort cytoreductive surgery for disseminated ovarian cancer in a UK setting: challenges and possibilities.
Fotopoulou C; Jones BP; Savvatis K; Campbell J; Kyrgiou M; Farthing A; Brett S; Roux R; Hall M; Rustin G; Gabra H; Jiao L; Stümpfle R
Arch Gynecol Obstet; 2016 Sep; 294(3):607-14. PubMed ID: 27040418
[TBL] [Abstract][Full Text] [Related]
17. Outcomes Associated With a Five-Point Surgical Site Infection Prevention Bundle in Women Undergoing Surgery for Ovarian Cancer.
Lippitt MH; Fairbairn MG; Matsuno R; Stone RL; Tanner EJ; Wick EC; Angarita AC; Roche KL; Levinson KL; Bergstrom JE; Sinno AK; Curless MS; Wethington S; Temkin SM; Efron J; Hobson D; Fader AN
Obstet Gynecol; 2017 Oct; 130(4):756-764. PubMed ID: 28885412
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant Chemotherapy Increases R0 Cytoreduction Rate But Does Not Improve Final Outcome in Advanced Epithelial Ovarian Cancer.
Medina-Franco H; Cortés-González R; Lambreton-Hinojosa F; Fimbres-Morales A; Vargas-Siordia JC
Ann Surg Oncol; 2017 May; 24(5):1330-1335. PubMed ID: 27995454
[TBL] [Abstract][Full Text] [Related]
19. Laparoscopic splenectomy both for primary cytoreductive surgery for advanced ovarian cancer and for secondary surgery for isolated spleen recurrence: feasibility and technique.
Macciò A; Sanna E; Lavra F; Chiappe G; Petrillo M; Madeddu C
BMC Surg; 2021 Oct; 21(1):380. PubMed ID: 34711237
[TBL] [Abstract][Full Text] [Related]
20. Rationale and study design of the CHIPPI-1808 trial: a phase III randomized clinical trial evaluating hyperthermic intraperitoneal chemotherapy (HIPEC) for stage III ovarian cancer patients treated with primary or interval cytoreductive surgery.
El Hajj H; Vanseymortier M; Hudry D; Bogart E; Abdeddaim C; Leblanc E; Le Deley MC; Narducci F
ESMO Open; 2021 Apr; 6(2):100098. PubMed ID: 33819750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
